Breaking News

Novasep Names Synthesis BU President

By Kristin Brooks | January 16, 2014

Van Nieuwenhove brings extensive experience

Thierry Van Nieuwenhove has been appointed president of Novasep’s Synthesis Business Unit in Pompey, France. Mr. Van Nieuwenhove joins the company from Ajinomoto-Omnichem, a European synthetic molecules custom manufacturing organization, where he held positions as director, and general manager and member of the board. His experience includes driving business unit growth, leading global teams including sales and business development, R&D, supply chain and purchasing, as well as mergers and acquisitions.
“We are thrilled to welcome Thierry to Novasep as president of the Synthesis Business Unit,” said Michel Spagnol, chief executive officer of Novasep. “His broad experience in driving multicultural custom synthesis businesses will complement our COMEX skills perfectly. Thierry possesses the dynamics to boost Novasep’s CMO business in all our key markets.”

Related Packaging:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus